USDA creates biotech office with industry-friendly mandate, sidelining EPA and FDA
S. 2692 — Agricultural Biotechnology Coordination Act · Filed by Alex Padilla (D-CA) · 1 cosponsor · Introduced Sep 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new Office of Biotechnology Policy within the U.S. Department of Agriculture, headed by a director reporting directly to the Secretary. The office will coordinate federal policies on biotechnology, biomanufacturing, and synthetic biology across USDA, EPA, FDA, and other agencies, handling research, regulation, labeling, commercialization, and trade. It requires consultation with biotech companies, academics, and farmers.
Why we flagged it
The bill establishes a new federal office explicitly tasked with 'prioritizing biotechnology' and coordinating 'commercialization, use, and trade' across multiple agencies. The framing emphasizes industry enablement and interagency alignment rather than independent safety review or public transparency, suggesting a structural bias toward streamlining approval pathways for biotech products.
What the text implies
- By centralizing biotech policy in a single USDA office reporting to the Secretary, the bill may reduce independent EPA and FDA input on environmental and food-safety reviews, potentially accelerating approvals without equivalent scrutiny.
- The requirement to 'consult' with biotech developers, academics, and producers—but no explicit mandate to consult environmental groups, consumer advocates, or public-health organizations—suggests asymmetric stakeholder access to policy formation.
The full analysis lists 4 implications of this text.
Who stands to gain
agricultural biotechnology companies; seed and crop-genetics firms; synthetic biology developers